Centogene is a holding company. Through its subsidiaries, Co. is a commercial-stage company that is focused on rare hereditary diseases. Co. has three reportable segments: pharmaceutical, which provides a variety of solutions to its pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring; diagnostics, which provides genetic sequencing and diagnostics services to its clients, who are typically physicians, laboratories or hospitals, either directly or through distributors; and COVID-19, which provides COVID-19 testing services to its clients such as COVID-19 antigen testing. The CNTG average annual return since 2019 is shown above.
The Average Annual Return on the CNTG average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CNTG average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CNTG average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|